Albert Bourla, Pfizer's CEO, said on Monday that the company may move overseas drug manufacturing back to the US if President Donald Trump's tariffs affect it. Bourla was speaking at TD Cowen's ...

Pfizer's (NYSE: PFE) shares have been southbound for the better part of three years, partly because it was unable to repeat its incredible financial performance during the early pandemic years. At ...

President Trump wants to bring pharmaceutical manufacturing back to the United States. Experts warn that tariffs could result ...

this new policy could increase the cost of manufacturing for Pfizer (even though most of their brand-name drugs for the US market are finished in the US or countries with strong regulations).

Trump hinted that the US will impose a 25%+ tariff on pharmaceuticals after giving US companies time to build more manufacturing capacity.

Pfizer, by the way, intends to achieve $1.5 billion in net cost savings by 2027 through its Manufacturing Optimization Program and currently has a strong debt profile. Pfizer’s $20.5 billion in ...

Pfizer PFE-1.48%decrease; red down pointing triangle had a problem. Doctors weren’t prescribing its migraine drug Nurtec because they assumed insurance coverage would be too much of a hassle. So ...

March 19 (Reuters) - Drugmaker Pfizer (PFE.N), opens new tab has sold its entire stake in Haleon (HLN.L), opens new tab for about 2.5 billion pounds ($3.24 billion) to institutional investors and ...

I'm projecting increased M&A activity in 2025, with Pfizer holding $20.5B in cash and $10B–$15B in acquisition firepower. I find valuation metrics compelling, trading at just 9x next year’s ...

Pfizer offers a substantial 6.7% dividend ... to deliver $1.5 billion of net cost savings from the first phase of its "Manufacturing Optimization Program" by the end of 2027.

KIRKLAND — Pfizer Canada’s IXIFI (infliximab for injection) will be available in Canada as of April 1, 2025. IXIFI is a biosimilar to Remicade (infliximab). It was approved by Health Canada ...